Safety Outcomes
No laboratory measurements showed abnormal findings that could be attributable to treatment with nebulised UFH and in particular, there were no significant differences in APTT between the two treatment groups.
There were no cases recorded of pulmonary bleeding, heparin induced thrombocytopaenia, or anaphylaxis during or immediately after administration of nebulised UFH, or any other adverse events.